Arovella Files IND for Lead CAR-iNKT Therapy as Cash Reserves Back 2026 Clinical Push

Arovella Therapeutics Limited ( (AU:ALA) ) just unveiled an announcement.

Arovella Therapeutics reported progress in the second quarter of FY26, highlighted by the filing of an Investigational New Drug application with the U.S. FDA for its lead allogeneic CAR-iNKT candidate ALA-101, selection of CRO SAPRO to run a first-in-human phase 1 trial in CD19-positive lymphoma and leukaemia across Australia and New Zealand, and confirmation of potent activity for its CLDN18.2-targeting CAR within the ALA-105 solid tumour program. The company ended the quarter with $19.4 million in cash, which it expects will fund completion of ALA-101 phase 1 enrolment and advancement of its solid tumour and armouring programs, while the in-licensing of additional CAR and iNKT-related technologies from Baylor College of Medicine and the board appointment of experienced drug developer Dr Andrew Nash are intended to strengthen its technology base, clinical transition and strategic positioning as it moves toward becoming a clinical-stage cell therapy player in 2026.

The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.

More about Arovella Therapeutics Limited

Arovella Therapeutics Limited is an Australian biotechnology company focused on developing allogeneic cell therapies based on invariant Natural Killer T (iNKT) cells. Its lead programs target blood cancers such as CD19-positive non-Hodgkin’s lymphoma and leukaemias, while its emerging pipeline extends into solid tumours, including gastric and pancreatic cancers, using chimeric antigen receptor (CAR) technologies and armouring approaches like IL-12-TM.

Average Trading Volume: 980,296

Technical Sentiment Signal: Hold

Current Market Cap: A$103.3M

Find detailed analytics on ALA stock on TipRanks’ Stock Analysis page.